Nevertheless, further trials are needed that evaluate the impact and predictive character of PD-1 + T lymphocytes in BAL of lung cancer patients for immunotherapy response in addition to analysing tumor samples for PD-L1 expression. This evidence concerns the gene PDCD1 and neoplasm.